This biotechnology company develops cell-free ribonucleic acid (RNA) arrays for high-throughput, real-time evaluation of multiple sequences and binding molecules. Their technology enables researchers to create new drugs targeting diseases that are currently considered undruggable.
Funding
$340K raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Current methods for RNA-targeted drug discovery are slow and labor-intensive due to limited research and development tools and incomplete understanding of RNA structure/function relationships. This makes the discovery process costly and time-consuming.
Solution
RevoNA Bio offers a high-throughput RNA biological platform that accelerates RNA-targeted drug discovery. The platform generates RNA datasets enriched with diverse information, which are then used to train a machine learning predictive engine. This integrated approach enables mechanistic elucidation of RNA structure-activity/function relationships specific to disease, hit identification and optimization, and safety assessment of proteomic and transcriptomic derived compounds. RevoNA's technology aims to reduce the cost and time required to bring RNA-targeted drugs to market.
Target Audience
RevoNA Bio's primary customers are biotechnology and pharmaceutical companies involved in RNA-targeted drug discovery, as well as researchers seeking to understand RNA structure and function in disease.
Features
- Patented high-throughput RNA biological platform for rapid data acquisition
- Cutting-edge machine learning predictive engine for data analysis and insights
- Mechanistic elucidation of RNA structure-activity/function relationships
- Hit identification and optimization capabilities
- Safety assessment of proteomic & transcriptomic derived compounds